Literature DB >> 12000755

Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture.

Xiongwen Zhang1, Lili Shu, Hajime Hosoi, K Gopal Murti, Peter J Houghton.   

Abstract

Mammalian target of rapamycin (mTOR) controls initiation of translation through regulation of ribosomal p70S6 kinase (S6K1) and eukaryotic translation initiation factor-4E (eIF4E) binding protein (4E-BP). mTOR is considered to be located predominantly in cytosolic or membrane fractions and may shuttle between the cytoplasm and nucleus. In most previous studies a single cell line, E1A-immortalized human embryonic kidney cells (HEK293), has been used. Here we show that in human malignant cell lines, human fibroblasts, and murine myoblasts mTOR is predominantly nuclear. In contrast, mTOR is largely excluded from the nucleus in HEK293 cells. Hybrids between HEK293 and Rh30 rhabdomyosarcoma cells generated cells co-expressing markers unique to HEK293 (E1A) and Rh30 (MyoD). mTOR distribution was mainly nuclear with detectable levels in the cytoplasm. mTOR isolated from Rh30 nuclei phosphorylated recombinant GST-4E-BP1 (Thr-46) in vitro and thus has kinase activity. We next investigated the cellular distribution of mTOR substrates 4E-BP, S6K1, and eIF4E. 4E-BP was exclusively detected in cytoplasmic fractions in all cell lines. S6K1 was localized in the cytoplasm in colon carcinoma, HEK293 cells, and IMR90 fibroblasts. S6K1 was readily detected in all cellular fractions derived from rhabdomyosarcoma cells. eIF4E was detected in all fractions derived from rhabdomyosarcoma cells but was not detectable in nuclear fractions from colon carcinoma HEK293 or IMR90 cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12000755     DOI: 10.1074/jbc.M202625200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  The expanding relevance of nuclear mTOR in carcinogenesis.

Authors:  Jung H Back; Arianna L Kim
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

2.  TOR1 and TOR2 have distinct locations in live cells.

Authors:  Thomas W Sturgill; Adiel Cohen; Melanie Diefenbacher; Mark Trautwein; Dietmar E Martin; Michael N Hall
Journal:  Eukaryot Cell       Date:  2008-08-22

3.  PPAR Gamma Coactivator 1 Beta (PGC-1β) Reduces Mammalian Target of Rapamycin (mTOR) Expression via a SIRT1-Dependent Mechanism in Neurons.

Authors:  Ying-Chun Liu; Xiao-Xiao Gao; Zhi-Guang Zhang; Zhao-Hua Lin; Qi-Lian Zou
Journal:  Cell Mol Neurobiol       Date:  2016-09-15       Impact factor: 5.046

4.  Mechanisms of regulation of RNA polymerase III-dependent transcription by TORC1.

Authors:  Yuehua Wei; Chi Kwan Tsang; X F Steven Zheng
Journal:  EMBO J       Date:  2009-07-02       Impact factor: 11.598

5.  The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts.

Authors:  Lili Shu; Peter J Houghton
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

6.  mTOR goes to the nucleus.

Authors:  Yu Jiang
Journal:  Cell Cycle       Date:  2010-03-01       Impact factor: 4.534

Review 7.  Mammalian target of rapamycin: a central node of complex signaling cascades.

Authors:  Yoh Dobashi; Yasutaka Watanabe; Chihiro Miwa; Sakae Suzuki; Shinichiro Koyama
Journal:  Int J Clin Exp Pathol       Date:  2011-06-14

Review 8.  Transcriptional and Epigenetic Regulation by the Mechanistic Target of Rapamycin Complex 1 Pathway.

Authors:  R Nicholas Laribee
Journal:  J Mol Biol       Date:  2018-10-23       Impact factor: 5.469

9.  Relation between outcomes and localisation of p-mTOR expression in gastric cancer.

Authors:  T Murayama; M Inokuchi; Y Takagi; H Yamada; K Kojima; J Kumagai; T Kawano; K Sugihara
Journal:  Br J Cancer       Date:  2009-02-17       Impact factor: 7.640

10.  Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycle.

Authors:  Margit Rosner; Christiane Fuchs; Nicol Siegel; Alessandro Valli; Markus Hengstschläger
Journal:  Hum Mol Genet       Date:  2009-06-08       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.